Cancer-derived extracellular vesicles (EVs) are regarded as having promising potential to be used as therapeutics and disease biomarkers. Mechanistically, EVs have been shown to function in most, if not all, steps of cancer progression. Cancer EVs, including small EVs (sEVs), contain unique biomolecular cargo, consisting of protein, nucleic acid and lipids. Through progress in the identification of this specific cargo, cancer biomarkers have been identified and developed, opening up novel and interesting opportunities for cancer diagnosis and prognosis. Intriguingly, we still lack a comprehensive understanding of the cancer-specific pathways that govern EV biogenesis in cancer cells. Filling this knowledge gap will rapidly improve cancer EV biomarkers, as it will also allow discrimination of the procancer and anticancer actions of those EVs. Even more promising is uncovering therapeutically targetable, tumour-specific EV pathways and content, which will generate novel classes of cancer therapies. This Review highlights the progress the cancer sEV field has made in the areas of biomarker discovery and validation as well as sEV-based therapeutics, highlights the challenges we are facing and identifies gaps in our knowledge, which currently prevent us from developing the full potential of sEVs in cancer diagnostic and therapy.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Outer membrane vesicles from a mosquito commensal mediate targeted killing of Plasmodium parasites via the phosphatidylcholine scavenging pathway
Nature Communications Open Access 24 August 2023
Cell Communication and Signaling Open Access 22 June 2023
Adipocyte-derived extracellular vesicles: bridging the communications between obesity and tumor microenvironment
Discover Oncology Open Access 08 June 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Galdiero, M. R., Marone, G. & Mantovani, A. Cancer inflammation and cytokines. Cold Spring Harb. Perspect. Biol. https://doi.org/10.1101/cshperspect.a028662 (2018).
Thomas, S. K., Lee, J. & Beatty, G. L. Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. EBioMedicine https://doi.org/10.1016/j.ebiom.2020.102662 (2020).
Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science https://doi.org/10.1126/science.aau6977 (2020).
Raposo, G. & Stahl, P. D. Extracellular vesicles: a new communication paradigm? Nat. Rev. Mol. Cell Biol. 20, 509–510 (2019).
Harding, C., Heuser, J. & Stahl, P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Meehan, K. & Vella, L. J. The contribution of tumour-derived exosomes to the hallmarks of cancer. Crit. Rev. Clin. Lab. Sci. 53, 121–131 (2016).
Kucharzewska, P. et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl Acad. Sci. USA 110, 7312–7317 (2013).
King, H. W., Michael, M. Z. & Gleadle, J. M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 12, 421 (2012). This early work shows that hypoxia, at least partly via the transcription factor hypoxia-inducible factor 1α, increases sEV secretion by breast cancer cells, identifying extracellular stress as a regulator of sEV abundance.
Bandari, S. K. et al. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018).
Keklikoglou, I. et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat. Cell Biol. 21, 190–202 (2019).
Wang, X. et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kgamma to promote pancreatic cancer metastasis. Cancer Res. 78, 4586–4598 (2018).
Hsu, Y. L. et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene 36, 4929–4942 (2017).
Li, L. et al. Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype. Cancer Res. 76, 1770–1780 (2016).
Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).
Fordjour, F. K., Daaboul, G. G. & Gould, S. J. A shared pathway of exosome biogenesis operates at plasma and endosome membranes. bioRxiv 10.1101/545228 (2019).
Lobb, R. J. et al. Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin. Proteomics https://doi.org/10.1002/pmic.201600432 (2017).
Wen, S. W. et al. Breast cancer-derived exosomes reflect the cell-of-origin phenotype. Proteomics 19, e1800180 (2019).
Kahlert, C. et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J. Biol. Chem. 289, 3869–3875 (2014).
Novo, D. et al. Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nat. Commun. 9, 5069 (2018).
Al-Nedawi, K. et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008). This is one of the initial descriptions that EVs can transfer functional oncogenic proteins, in this case EGFR, to recipient cells.
Demory Beckler, M. et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol. Cell Proteom. 12, 343–355 (2013).
Hurwitz, S. N. et al. Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers. Oncotarget 7, 86999–87015 (2016).
Castillo, J. et al. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann. Oncol. 29, 223–229 (2018).
Temoche-Diaz, M. M. et al. Distinct mechanisms of microRNA sorting into cancer cell-derived extracellular vesicle subtypes. eLife https://doi.org/10.7554/eLife.47544 (2019). This study identifies selective and non-selective miRNA sorting into two different sEV subpopulations.
Fang, T. et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018).
Yan, W. et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat. Cell Biol. 20, 597–609 (2018).
Cooks, T. et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018).
Teng, Y. et al. MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat. Commun. 8, 14448 (2017).
Shen, M. et al. Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2. Cancer Res. 79, 3608–3621 (2019).
Hashimoto, K. et al. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl Acad. Sci. USA 115, 2204–2209 (2018).
Au Yeung, C. L. et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat. Commun. 7, 11150 (2016).
O’Brien, K., Breyne, K., Ughetto, S., Laurent, L. C. & Breakefield, X. O. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat. Rev. Mol. Cell Biol. https://doi.org/10.1038/s41580-020-0251-y (2020).
McKenzie, A. J. et al. KRAS-MEK signaling controls Ago2 sorting into exosomes. Cell Rep. 15, 978–987 (2016).
Le, M. T. et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J. Clin. Invest. 124, 5109–5128 (2014).
Clancy, J. W., Zhang, Y., Sheehan, C. & D’Souza-Schorey, C. An ARF6-exportin-5 axis delivers pre-miRNA cargo to tumour microvesicles. Nat. Cell Biol. 21, 856–866 (2019).
Keller, S., Ridinger, J., Rupp, A. K., Janssen, J. W. & Altevogt, P. Body fluid derived exosomes as a novel template for clinical diagnostics. J. Transl Med. 9, 86 (2011).
Anfossi, S., Babayan, A., Pantel, K. & Calin, G. A. Clinical utility of circulating non-coding RNAs - an update. Nat. Rev. Clin. Oncol. 15, 541–563 (2018).
Xu, R. et al. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat. Rev. Clin. Oncol. 15, 617–638 (2018).
Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531–548 (2017).
Maus, R. L. G. et al. Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017).
Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018). This study describes PDL1 on melanoma cell-derived EVs which is inducible by IFNγ and could be a mechanism of systemic suppression of anticancer T cell responses.
Theodoraki, M. N., Yerneni, S. S., Hoffmann, T. K., Gooding, W. E. & Whiteside, T. L. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin. Cancer Res. 24, 896–905 (2018).
Poggio, M. et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell 177, 414–427 e413 (2019).
Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell Infiltration and PD-L1. Cancer Res. 75, 2139–2145 (2015).
Capello, M. et al. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat. Commun. 10, 254 (2019).
Aung, T. et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc. Natl Acad. Sci. USA 108, 15336–15341 (2011).
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04427475 (2020).
Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012).
Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015). The authors describe how different integrin compositions of EVs impact their uptake in different organs, and clinical data suggest that integrin profiles could predict organ-specific metastasis.
Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).
Sceneay, J., Smyth, M. J. & Moller, A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 32, 449–464 (2013).
Costa-Silva, B. et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015).
Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177–182 (2015). This publication shows that GPC1 on EVs could be used to differentiate patients with pancreatic cancer from healthy individuals, with a suggestion of using these EVs as a cancer biomarker.
Frampton, A. E. et al. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget 9, 19006–19013 (2018).
Qian, J. Y., Tan, Y. L., Zhang, Y., Yang, Y. F. & Li, X. Q. Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy. Oncol. Lett. 16, 1253–1258 (2018).
Lucien, F. et al. Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases. Oncotarget 10, 1045–1055 (2019).
Buscail, E. et al. CD63-GPC1-positive exosomes coupled with CA19-9 offer good diagnostic potential for resectable pancreatic ductal adenocarcinoma. Transl Oncol. 12, 1395–1403 (2019).
Yang, K. S. et al. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.aal3226 (2017).
Keller, L. & Pantel, K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat. Rev. Cancer 19, 553–567 (2019).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
Tutrone, R. et al. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial biopsy with a PSA 2-10 ng/mL. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-020-0237-z (2020).
McKiernan, J. et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/ml at initial biopsy. Eur. Urol. 74, 731–738 (2018).
McKiernan, J. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2, 882–889 (2016).
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03031418 (2017).
Zhou, R. et al. The decade of exosomal long RNA species: an emerging cancer antagonist. Mol. Cancer 17, 75 (2018).
Hannafon, B. N. et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 18, 90 (2016).
Manier, S. et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood 129, 2429–2436 (2017).
Asano, N. et al. A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. Nat. Commun. 10, 1299 (2019).
Worst, T. S. et al. miR-10a-5p and miR-29b-3p as extracellular vesicle-associated prostate cancer detection markers. Cancers https://doi.org/10.3390/cancers12010043 (2019).
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03895216 (2019).
Li, Z. et al. Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Lett. 432, 237–250 (2018).
Yu, S. et al. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. Gut 69, 540–550 (2020).
Chen, S., Zhu, X. & Huang, S. Clinical applications of extracellular vesicle long RNAs. Crit. Rev. Clin. Lab. Sci. https://doi.org/10.1080/10408363.2020.1751584 (2020).
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03830619 (2019).
Thakur, B. K. et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014).
Allenson, K. et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann. Oncol. 28, 741–747 (2017).
Yang, D. et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics 10, 3684–3707 (2020).
Xie, X. et al. Eliminating blood oncogenic exosomes into the small intestine with aptamer-functionalized nanoparticles. Nat. Commun. 10, 5476 (2019). In this article, the capacity of selectively ablating cancer-derived EVs by charged mesoporous silica nanoparticles functionalized with EGFR-targeting aptamers is demonstrated in animal models and blood of patients with lung cancer.
Marleau, A. M., Chen, C. S., Joyce, J. A. & Tullis, R. H. Exosome removal as a therapeutic adjuvant in cancer. J. Transl Med. 10, 134 (2012).
Andre, F. et al. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20, A28–A31 (2002).
Andre, F. et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360, 295–305 (2002).
Wolfers, J. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7, 297–303 (2001).
Chen, W. et al. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur. J. Immunol. 36, 1598–1607 (2006).
Rodrigues, G. et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019).
Wen, S. W. et al. The biodistribution and immune suppressive effects of breast cancer-derived exosomes. Cancer Res. 76, 6816–6827 (2016).
Diamond, J. M. et al. Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol. Res. 6, 910–920 (2018).
Kitai, Y. et al. DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017).
Takahashi, A. et al. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. Nat. Commun. 8, 15287 (2017).
Raposo, G. et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183, 1161–1172 (1996).
Zitvogel, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4, 594–600 (1998).
Escudier, B. et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J. Transl Med. 3, 10 (2005).
Morse, M. A. et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl Med. https://doi.org/10.1186/1479-5876-3-9 (2005).
Segura, E., Amigorena, S. & Thery, C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cell Mol. Dis. 35, 89–93 (2005).
Segura, E. et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106, 216–223 (2005).
Viaud, S. et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J. Immunother. 34, 65–75 (2011).
Besse, B. et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5, e1071008 (2016).
Cheng, L., Wang, Y. & Huang, L. Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol. Ther. 25, 1665–1675 (2017).
Zhu, L. et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics 7, 2732–2745 (2017).
Fu, W. et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat. Commun. 10, 4355 (2019). This work in preclinical models shows that EVs derived from CAR T cells contain CAR and have similar anticancer efficacies to CAR T cells but cannot be inhibited by PD1.
Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).
Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503 (2017).
Mendt, M. et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight https://doi.org/10.1172/jci.insight.99263 (2018).
Kooijmans, S. A. A. et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control. Rel. 172, 229–238 (2013).
Haney, M. J. et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control. Rel. 207, 18–30 (2015).
Kim, M. S. et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine 14, 195–204 (2018).
Kooijmans, S. A. et al. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J. Extracell. Vesicles 5, 31053 (2016).
Stickney, Z., Losacco, J., McDevitt, S., Zhang, Z. & Lu, B. Development of exosome surface display technology in living human cells. Biochem. Biophys. Res. Commun. 472, 53–59 (2016).
Kanuma, T. et al. CD63-mediated antigen delivery into extracellular vesicles via DNA vaccination results in robust CD8+ T cell responses. J. Immunol. 198, 4707–4715 (2017).
Morishita, M., Takahashi, Y., Matsumoto, A., Nishikawa, M. & Takakura, Y. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials 111, 55–65 (2016).
Kowal, J. et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc. Natl Acad. Sci. USA 113, E968–E977 (2016).
Liang, G. et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J. Nanobiotechnol. 18, 10 (2020).
Yim, N. et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat. Commun. 7, 12277 (2016).
Shen, B., Wu, N., Yang, J. M. & Gould, S. J. Protein targeting to exosomes/microvesicles by plasma membrane anchors. J. Biol. Chem. 286, 14383–14395 (2011).
Fang, Y. et al. Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol. 5, e158 (2007).
Sterzenbach, U. et al. Engineered exosomes as vehicles for biologically active proteins. Mol. Ther. 25, 1269–1278 (2017).
Baietti, M. F. et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 14, 677–685 (2012). This study provides important mechanistic insights into how syndecans, heparan sulfate proteoglycans, and their cytoplasmic adaptor syntenin are essential mediators of sEV biogenesis.
Ridder, K. et al. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology 4, e1008371 (2015). This is an early description of how functional Cre recombinase mRNA can be delivered by EVs to immune cell lineages in the tumour microenvironment, causing recombination events in Cre reporter mice.
Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal. Transduct. Target. Ther. 4, 35 (2019).
Hong, Y. et al. Exosome as a vehicle for delivery of membrane protein therapeutics, PH20, for enhanced tumor penetration and antitumor efficacy. 28, 1703074 (2018).
Lai, C. P. et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8, 483–494 (2014). This study uses fluorescent and luminescent markers to demonstrate a quick EV uptake by cells and the rapid translation of EV-contained mRNA.
Wiklander, O. P. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles 4, 26316 (2015).
van der Meel, R. et al. Smart cancer nanomedicine. Nat. Nanotechnol. 14, 1007–1017 (2019).
Zipkin, M. Exosome redux. Nat. Biotechnol. 37, 1395–1400 (2019).
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03608631 (2018).
Gorgens, A. et al. Optimisation of imaging flow cytometry for the analysis of single extracellular vesicles by using fluorescence-tagged vesicles as biological reference material. J. Extracell. Vesicles 8, 1587567 (2019).
Ricklefs, F. L. et al. Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. J. Extracell. Vesicles 8, 1588555 (2019).
Jones, P. S. et al. Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma. EBioMedicine 48, 23–35 (2019).
de Jong, O. G. et al. A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA. Nat. Commun. 11, 1113 (2020).
Liang, K. et al. Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-016-0021 (2017).
Wang, J. et al. Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. Sci. Adv. 6, eaax3223 (2020).
Abusamra, A. J. et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cell Mol. Dis. 35, 169–173 (2005).
Rivoltini, L. et al. TNF-related apoptosis-inducing ligand (TRAIL)-armed exosomes deliver proapoptotic signals to tumor site. Clin. Cancer Res. 22, 3499–3512 (2016).
Ghossoub, R. et al. Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2. Nat. Commun. 5, 3477 (2014).
Roucourt, B., Meeussen, S., Bao, J., Zimmermann, P. & David, G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res. 25, 412–428 (2015).
Ostrowski, M. et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. https://doi.org/10.1038/ncb2000 (2010).
Bobrie, A. et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 72, 4920–4930 (2012).
Zhang, H. & Lyden, D. Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. Nat. Protoc. 14, 1027–1053 (2019).
Zhang, H. et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018).
Fedele, C., Singh, A., Zerlanko, B. J., Iozzo, R. V. & Languino, L. R. The alphavbeta6 integrin is transferred intercellularly via exosomes. J. Biol. Chem. 290, 4545–4551 (2015).
Bellavia, D. et al. Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth. Theranostics 7, 1333–1345 (2017).
Yang, Y. et al. Virus-mimetic fusogenic exosomes for direct delivery of integral membrane proteins to target cell membranes. Adv. Mater https://doi.org/10.1002/adma.201605604 (2017).
Shtam, T. A. et al. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun. Signal. 11, 88 (2013).
Kim, M. S. et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12, 655–664 (2016).
Sato, Y. T. et al. Engineering hybrid exosomes by membrane fusion with liposomes. Sci. Rep. 6, 21933 (2016).
Fuhrmann, G., Serio, A., Mazo, M., Nair, R. & Stevens, M. M. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J. Control. Rel. 205, 35–44 (2015).
Zhang, H. et al. Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA. Cancer Sci. 109, 629–641 (2018).
Lai, C. P. et al. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015).
Hung, M. E. & Leonard, J. N. Stabilization of exosome-targeting peptides via engineered glycosylation. J. Biol. Chem. 290, 8166–8172 (2015).
Choi, D. S., Kim, D. K., Kim, Y. K. & Gho, Y. S. Proteomics of extracellular vesicles: Exosomes and ectosomes. Mass. Spectrom. Rev. 34, 474–490 (2015).
Van Deun, J. et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat. Methods 14, 228–232 (2017).
Chevillet, J. R. et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc. Natl Acad. Sci. USA 111, 14888–14893 (2014).
Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).
Plebanek, M. P. et al. Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche. Nat. Commun. 8, 1319 (2017).
Zomer, A. et al. In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 161, 1046–1057 (2015).
Ludwig, N. & Whiteside, T. L. Potential roles of tumor-derived exosomes in angiogenesis. Expert Opin. Ther. Targets 22, 409–417 (2018).
Webber, J. P. et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 34, 290–302 (2015).
Yokoi, A. et al. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat. Commun. 8, 14470 (2017).
Luga, V. et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151, 1542–1556 (2012).
Zhang, L. et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527, 100–104 (2015).
The authors thank M. Smyth and M. Ernst for their comments and suggestions during the writing process. It is with regret that not all relevant studies could be cited due to space limitations. This Review was supported by Australian National Breast Cancer Foundation (IIRS-18-159) and Australia National Health and Medical Research Council (APP1185907) grants to A.M. R.J.L. is supported by the CSIRO Synthetic Biology Future Science Platform.
A.M. and R.J.L. are listed as inventors on patents owned by the QIMR Berghofer Medical Research Institute on the use of extracellular vesicles as a cancer biomarker.
Peer review information
Nature Reviews Cancer thanks the anonymous reviewers for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The in vivo localization at which an extracellular vesicle accumulates as a result of size or surface content.
- Recipient cells
Cells that, in the extracellular vesicle context, take up extracellular vesicles by one or several mechanisms, including for example receptor-mediated uptake, phagocytosis, macropinocytosis or various forms of endocytosis.
The term used to classify vesicles that are directly formed by budding of the plasma membrane.
- sEV cargo
The content of a small extracellular vesicle (sEV), which includes proteins, nucleic acids and lipids, as well as metabolites, derived from the cell of origin and/or artificially engineered into sEVs.
- Liquid biopsy
The use of bodily fluids to provide information on the presence (or absence) of certain conditions, including molecular information (for example, genetic alterations), as an alternative and/or addition to obtaining tissue biopsy samples.
Targeted preferentially and/or specifically to a certain individual organ or tissue in the body.
- M1 macrophages
Subset of macrophages with a proinflammatory phenotype, including the secretion of IL-6 and tumour necrosis factor.
- Chimeric antigen receptor
(CAR). An engineered, artificial cell surface receptor that bestows a specific function on the cell.
Small proteins that are engineered antibody equivalents to specifically recognize and bind target sequences, with an intentional use in diagnostic and therapeutic applications.
- Optogenetic tools
Optogenetic tools utilise light-sensitive proteins for precise spatial and temporal control of protein activity.
About this article
Cite this article
Möller, A., Lobb, R.J. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer 20, 697–709 (2020). https://doi.org/10.1038/s41568-020-00299-w
This article is cited by
Cell Communication and Signaling (2023)
Fusobacterium nucleatum-derived small extracellular vesicles facilitate tumor growth and metastasis via TLR4 in breast cancer
BMC Cancer (2023)
Molecular Cancer (2023)
Ultrasensitive and colorimetric small extracellular vesicles (sEVs) analysis via dual-cycle signal tool
Journal of Analytical Science and Technology (2023)
Ceramide present in cholangiocarcinoma-derived extracellular vesicle induces a pro-inflammatory state in monocytes
Scientific Reports (2023)